Logo image
Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
Journal article   Open access   Peer reviewed

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer

Caspian Oliai, Rachelle Lanciano, Brian Sprandio, Jun Yang, John Lamond, Steven Arrigo, Michael Good, Michael Mooreville, Bruce Garber and Luther W. Brady
Journal of radiation oncology, v 2(1), pp 63-70
01 Mar 2013
PMID: 23504305
url
https://doi.org/10.1007/s13566-012-0067-2View
Published, Version of Record (VoR)CC BY V4.0 Open

Abstract

Life Sciences & Biomedicine Oncology Science & Technology
Objective The low alpha/beta ratio of prostate cancer suggests that hypofractionated schemes of dose-escalated radiotherapy should be advantageous. We report our experience using stereotactic body radiation therapy (SBRT) for the primary treatment of prostate cancer to assess efficacy and toxicity. Methods From 2007 to 2010, 70 patients (51 % low risk, 31 % intermediate risk, and 17 % high risk) with localized prostate cancer were treated with SBRT using the CyberKnife system. One-third of patients received androgen deprivation therapy. Doses of 37.5 Gy (n=29), 36.25 Gy (n=36), and 35 Gy (n=5) were administered in five fractions and analyzed as high dose (37.5 Gy) vs. low dose (36.25 and 35 Gy). Results At a median 27 and 37 months follow-up, the low and high dose groups' median PSA nadir to date was 0.3 and 0.2 ng/ml, respectively. The 3-year freedom from biochemical failure (FFBF) was 100 %, 95.0 % and 77.1 % for the low-, intermediate-and high-risk patients. A dose response was observed in intermediate-and high-risk patients with 72 % vs. 100 % 3-year FFBF for the low and high dose groups, respectively (p=0.0363). Grade III genitourinary toxicities included 4 % acute and 3 % late (all high dose). Potency was preserved in 83 % of hormone naive patients. Conclusion CyberKnife dose escalated SBRT for low-, intermediate-and high-risk prostate cancer exhibits favorable efficacy with acceptable toxicity.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Oncology
Logo image